UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

The Lancet (British edition), 2017-09, Vol.390 (10099), p.1048-1060

2017

Link zum Volltext

Verfügbarkeit prüfen

Fewer fractions of adjuvant external beam radiotherapy for early breast cancer are safe and effective and can now be the standard of care. Why the UK's NICE accepts fewer fractions as the standard of care for adjuvant radiotherapy in early breast cancer

Breast (Edinburgh), 2010-06, Vol.19 (3), p.159-162

Harnett, Adrian

2010

Link zum Volltext

Verfügbarkeit prüfen

Fewer fractions of adjuvant external beam radiotherapy for early breast cancer are safe and effective and can now be the standard of care

Breast (Edinburgh), 2010-06, Vol.19 (3), p.159-162

Harnett, Adrian

2010

Link zum Volltext

Verfügbarkeit prüfen

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

The Lancet (British edition), 2020-05, Vol.395 (10237), p.1613-1626

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial

The Lancet (British edition), 1996-09, Vol.348 (9029), p.708-713

1996

Link zum Volltext

Verfügbarkeit prüfen

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

Journal of clinical oncology, 2020-10, Vol.38 (28), p.3261-3272

2020

Link zum Volltext

Verfügbarkeit prüfen

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1688-1700

2017

Link zum Volltext

Verfügbarkeit prüfen

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

The Lancet (British edition), 2019-06, Vol.393 (10191), p.2599-2612

2019

Link zum Volltext

Verfügbarkeit prüfen

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Radiotherapy and oncology, 2016-07, Vol.120 (1), p.114-118

2016

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and Management of Menopause: The National Institute of Health and Care Excellence (NICE) Guideline

JAMA internal medicine, 2016-08, Vol.176 (8), p.1205

2016

Link zum Volltext

Verfügbarkeit prüfen

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

The New England journal of medicine, 2011-10, Vol.365 (15), p.1396-1405

2011

Link zum Volltext

Verfügbarkeit prüfen

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)

Radiotherapy and oncology, 2011-07, Vol.100 (1), p.93-100

2011

Link zum Volltext

Verfügbarkeit prüfen

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

British journal of cancer, 2019-04, Vol.120 (9), p.883-895

2019

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction

British journal of surgery, 2020-06, Vol.107 (7), p.832-844

2020

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab-associated cardiac events in the Persephone trial

British journal of cancer, 2016-12, Vol.115 (12), p.1462-1470

2016

Link zum Volltext

Verfügbarkeit prüfen

The Breast Angiosarcoma Surveillance Study

European journal of surgical oncology, 2020-02, Vol.46 (2), p.e47-e47

2020

Link zum Volltext

Verfügbarkeit prüfen

Risk of premature menopause after treatment for Hodgkin's lymphoma

JNCI : Journal of the National Cancer Institute, 2014-09, Vol.106 (9), p.1

2014

Link zum Volltext

Verfügbarkeit prüfen

28. The Breast Angiosarcoma Surveillance Study (BRASS)

European journal of surgical oncology, 2019-05, Vol.45 (5), p.884-884

2019

Link zum Volltext

Verfügbarkeit prüfen

The iBRA-2 (immediate breast reconstruction and adjuvant therapy audit) study: protocol for a prospective national multicentre cohort study to evaluate the impact of immediate breast reconstruction on the delivery of adjuvant therapy

BMJ open, 2016-10, Vol.6 (10), p.e012678-e012678

2016

Link zum Volltext

Verfügbarkeit prüfen

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.506-506

2018

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors

British journal of cancer, 2013-06, Vol.108 (11), p.2399-2406

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019)

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P4-P4-11-03

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom

British journal of radiology, 2015-01, Vol.88 (1056), p.20150453-20150453

2015

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and treatment of early breast cancer, including locally advanced disease--summary of NICE guidance

BMJ (Online), 2009-02, Vol.338, p.b438

2009

Link zum Volltext

Verfügbarkeit prüfen

Angiosarcoma of the scalp presenting in association with borderline malignant phyllodes tumour of the breast

Sarcoma, 2003-01, Vol.2003 (3-4), p.173-176

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(35)

Publikationsform

Sprache

Englisch
(41)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Bmj
(4)
The Lancet
(4)
British Journal Of Cancer
(3)
Radiotherapy And Oncology
(3)
Bmj Open
(2)
Breast
(2)
British Journal Of Radiology
(2)
European Journal Of Surgical Oncology
(2)
Journal Of Clinical Oncology
(2)
Sarcoma
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Fewer fractions of adjuvant external beam radiotherapy for early breast cancer are safe and effective and can now be the standard of care. Why the UK's NICE accepts fewer fractions as the standard of care for adjuvant radiotherapy in early breast cancer

Fewer fractions of adjuvant external beam radiotherapy for early breast cancer are safe and effective and can now be the standard of care

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Diagnosis and Management of Menopause: The National Institute of Health and Care Excellence (NICE) Guideline

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction

Trastuzumab-associated cardiac events in the Persephone trial

The Breast Angiosarcoma Surveillance Study

Risk of premature menopause after treatment for Hodgkin's lymphoma

28. The Breast Angiosarcoma Surveillance Study (BRASS)

The iBRA-2 (immediate breast reconstruction and adjuvant therapy audit) study: protocol for a prospective national multicentre cohort study to evaluate the impact of immediate breast reconstruction on the delivery of adjuvant therapy

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors

Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019)

Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom

Diagnosis and treatment of early breast cancer, including locally advanced disease--summary of NICE guidance

Angiosarcoma of the scalp presenting in association with borderline malignant phyllodes tumour of the breast

Suchergebnisse filtern